Manon Boisclair

CEO & Founder, InnovID B2 | MS, MBA, ICD.D

Role: Associate

Sites: CDL-Montreal, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Streams: Artificial Intelligence, Cancer, Health & Wellness

Manon is a Canadian/American entrepreneur and founder of InnovID B2, a boutique firm in impact consulting in life science and sustainability. She has 20+ years of international experience in executive management roles with NASDAQ-listed BioPharma companies (Merck, Novartis, Celgene and Intercept) in the US, Canada and Europe. She has extensive global operations, go-to-market, medical/marketing strategy expertise, has launched several oncology blockbusters and worked on early pipeline compounds in rare diseases and NASH.

Involved in private equity, Manon is an LP with Accelia Capital and an adviser to VC firms in life sciences. She is also a seasoned angel investor with a solid track record in business development, governance, and Series A & B fundraising. Manon is a board director to PE companies as well as on the governance committee of the Canadian Cancer Society.

Active in the startup ecosystem, she is a mentor to several entrepreneurs affiliated with Creative Destruction Lab, Centech, CTS and District3. Manon fosters trailblazing entrepreneurs who are laser-focused on the rapid scaling of their solutions. She is a healthcare clinician with a master’s from University of Montreal and an executive MBA from McGill/HEC Montreal. In addition, Manon is a certified corporate board director from Harvard Business School, the Institute of Corporate Directors and obtained an ESG designation from Competent Boards.